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241 Evidence for a cystic ﬁbrosis enteropathy
M. Adriaanse1, L. van der Sande1, E. Dompeling1, W. Buurman2, A. Vreugdenhil1.
1Maastricht University Medical Center, Paediatrics, Maastricht, Netherlands;
2Maastricht University Medical Center, General Surgery, Maastricht, Netherlands
Objectives: Previous studies suggest a cystic ﬁbrosis (CF) enteropathy. It can be
hypothesized that this enteropathy contributes to the characterizing poor nutritional
status, gradual decline in pulmonary function and subsequent mortality in these
patients. This study aimed to investigate enterocyte damage and intestinal inﬂam-
mation in CF, and its relation to pulmonary function.
Methods: Serum intestinal fatty acid binding protein (I-FABP), a circulating marker
for enterocyte damage, was analysed in a cohort of 72 CF patients and 107 controls.
Data regarding faecal calprotectin − a marker for intestinal inﬂammation, pulmonary
function, and comorbidities were extracted from the medical charts.
Conclusion: I-FABP levels were signiﬁcantly elevated in CF patients as compared
to controls (502 pg/ml [281–774] and 288 pg/ml [147–349], p< 0.001). Serum
I-FABP was negatively correlated with forced expiratory volume (FEV1) in children
(rp −0.589, p< 0.05, n = 15). Calprotectin levels were elevated in 93% of CF pa-
tients, and correlated positively with age (rs 0.350, p< 0.05, n = 20) and negatively
with FEV1 in adults (rs −0.440, p< 0.01), even after correction for age. Patients with
CF-related diabetes (CFRD), exocrine pancreatic insufﬁciency (EPI) and patients
using protonpompinhibitors (PPIs), showed elevated calprotectin levels.
In this study, for the ﬁrst time, enterocyte damage in CF is demonstrated using
I-FABP as a marker. Presence of intestinal inﬂammation in CF patients was
conﬁrmed and now shown to be worse in EPI, CFRD and PPI use. Moreover, the
data of this study suggest a relation between intestinal damage and inﬂammation
and pulmonary function.
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Objectives: Evaluate the size and the contractility of the gallbladder (GB) in cystic
ﬁbrosis (CF) patients with and without pancreatic insufﬁciency.
Methods: There were included 76 individuals with age ranged from 1−18 years
of age, 38 with CF (CF-Group) and 38 controls (control-group) matched for sex
and age. All individuals were submitted to hepatic ultrasonography. The method of
Van de Kamer was used to assess pancreatic function. The CF-Group was rated for
presence (CF1) or absence (CF2) from steatorrhea. The evaluation of the gallbladder
(GB) was obtained by:
1. greater longitudinal dimension,
2. larger anteroposterior size, and
3. GB area.
These measurements were obtained on fasting, 30 and 60 minutes after ingestion of
food. From the results we calculated the GB contractility index (GBCI). To compare
the measurements of the GB in CF patients versus controls was employed student
t test for paired samples. To compare CF1 and CF2 groups was used the U Mann-
Whitney test. In our study, the mean values of the measures 1, 2 and 3 for the CF and
controls groups were: (12:45±51.53mm, 15.25mm ±4.98, 292.94±676mm2) and
(11:43±57.28mm, 17.70mm ±5.20, 344.17±896.65mm2) respectively (p< 0.05).
The GBCI on 30 and 60 minutes was also lower in CF-Group compared with the
control group and no signiﬁcant difference between subgroups in CF1 and CF2 was
found.
Conclusion: CF patients have minor GB dimension and contractility than the
control group. The GBCI was not associated with the presence or absence of
steatorrhoea in CF patients.
243 Transient elastography and abdominal ultra-sound investigation
of adult CF patients monitored at the Copenhagen CF centre
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Objectives: To determine the prevalence of ﬁbrosis/cirrhosis among adult Danish
CF patients and to compare the performance of transient elastography (TE) to ultra-
sound of abdomen.
Methods: Cross-sectional study. All patient attending the Adult CF Centre at
Copenhagen University Hospital, Rigshospitalet were invited to participate. In
conjunction with a planned (non-acute) outpatient visit the patients had TE &
ultrasound of upper abdomen performed. At the same visit blood samples were
drawn for hemoglobin, leucocyte, thrombocyte levels, liver enzymes, tests for auto-
immune hepatitis as well as samples for markers of ﬁbrosis.
Results: By January 2013 49 patients have been included. A ﬁfth (9/44) of the
patients had elevated alanine amino-transferase (>45U/l). TE could not be done in
3 (6%). Liver stiffness measurement were normal, with signs of ﬁbrosis or cirrhosis
(<7.7, >7.7<13.8 & >13.8 kPa) for 83%, 13% and 4%, respectively. Two patients
with high ﬁbroelastase values (11.3 & 20.6 kPa) also had sonographical sign of
ﬁbrosis/cirrhosis. In both cases the patients and treating clinicians were unaware of
signs of substantial liver affection. The highest liver stiffness value (35.8 kPa) was
found in a patient previously diagnosed with cirrhosis.
Conclusion: At a routine visit to the adult CF clinic 20% of the patients displayed
elevated liver enzymes. Seventeen percent of the patients had increased liver
stiffness values, with 4% of the population having liver stiffness values (as well
as ultrasound examination) indicative of cirrhosis. TE seems to be valuable in the
evaluation of CF-related liver disease.
244 The effect of lubiprostone on human duodenal biopsy samples
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Objectives: To study the effect of lubiprostone (Lp) on human duodenal biopsy
tissue. Previous work suggests that Lp activates CLC-2in the gut, but not CFTR. Lp
could therefore provide an alternative treatment to alleviate obstructive intestinal
disease observed in cystic ﬁbrosis patients.
Methods: Tissue samples from 9 female and 4 male patients, age 8 to 15 years
(mean 12 years) were mounted in an Ussing chamber with standard Krebs both
sides. Mean tissue resistance was 33±5 ohms.cm2 (n = 13). Control measurements
were taken for 5 minutes and then glucose added apically to conﬁrm tissue viability.
10mA of current was injected to calculate the equivalent short circuit current (ISC).
1mM Lp was added apically. Statistical signiﬁcance was tested using Student’s t-test
and assumed at the 5% level.
Conclusion: Addition of Lp shifted Vte from 0.56±0.16mV to 0.73±0.19mV,
a mean shift of 0.17±0.05mV. This was associated with a signiﬁcant in-
crease in ISC from 25.2±9.70mA/cm2 to 29.9±9.90mA/cm2, a mean increase of
4.72±2.10mA/cm2. These data suggest that Lp increases ion movement across
human duodenal biopsy samples. The role of CFTR and CLC-2 in this ion
movement is currently being investigated by examining the effect of the inhibitors
CFTRinh172 (to block CFTR) and cadmium (to block CLC-2).
